Product logins

Find logins to all Clarivate products below.


Blog: Biopharma

Here you will find relevant articles and insight into all Clarivate related products and news.

The competitive signals hiding in plain sight for biopharma The competitive signals hiding in plain sight for biopharma
Blog May 8, 2026
The competitive signals hiding in plain sight for biopharma
Biopharma Business Development Clinical trials
Five lessons learned deploying agentic AI in the life sciences Five lessons learned deploying agentic AI in the life sciences
Blog April 30, 2026
Five lessons learned deploying agentic AI in the life sciences
AI
Target selection and safety assessment: Navigating early decisions that shape drug development Target selection and safety assessment: Navigating early decisions that shape drug development
Blog March 27, 2026
Target selection and safety assessment: Navigating early decisions that shape drug development
Development Pharma Regulatory
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
Blog March 26, 2026
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
GLP-1 Metabolic
Why longevity might be biopharma's next big thing: The science and business converge Why longevity might be biopharma's next big thing: The science and business converge
Blog March 2, 2026
Why longevity might be biopharma's next big thing: The science and business converge
Gerontology
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers
Biopharma Biotech Clinical trials
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Biopharma Biotech Clinical trials
Relacorilant:  when evidence meets the established evidence bar Relacorilant:  when evidence meets the established evidence bar
Blog February 24, 2026
Relacorilant: when evidence meets the established evidence bar
FDA Regulatory Safety

Biopharma

Boost in Paragraph Four patent challenges drives competitive generics marketplace Boost in Paragraph Four patent challenges drives competitive generics marketplace
Blog March 28, 2019
Boost in Paragraph Four patent challenges drives competitive generics marketplace
In multiple myeloma, B-cell maturation antigen emerges as promising target In multiple myeloma, B-cell maturation antigen emerges as promising target
Blog February 26, 2019
In multiple myeloma, B-cell maturation antigen emerges as promising target
Blog January 24, 2019
Will Specialty Drug Exclusions by PBM Giants Bring Down Drug Spending for 2019?
Blog January 23, 2019
Heart Failure With Preserved Ejection Fraction (HFpEF): Pipeline Overview
Blog January 17, 2019
71% of surveyed MCOs have outcomes-based contracts with pharma or plan to by the end of 2019
Neuroscience lures dealmakers despite drug development challenges Neuroscience lures dealmakers despite drug development challenges
Blog January 15, 2019
Neuroscience lures dealmakers despite drug development challenges
Blog January 7, 2019
Top Seven Predictions for PBM industry in 2019
Blog December 27, 2018
Challenges in SLE Drug Development: The Key Hurdles
How regulation, innovation, quality and access are inevitably intertwined How regulation, innovation, quality and access are inevitably intertwined
Blog November 13, 2018
How regulation, innovation, quality and access are inevitably intertwined
Blog November 1, 2018
Mutual Self-Interest: Joint Venture Payer-Provider Health Plans